Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0
Laboratory animals are the foundational conditions and indispensable technical support in life science research and biomedical industry development. The scientific development of animal models of diseases is of great significance to biomedical research and industrial development. In light of the boo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Laboratory Animal and Comparative Medicine
2023-10-01
|
| Series: | Shiyan dongwu yu bijiao yixue |
| Subjects: | |
| Online Access: | https://www.slarc.org.cn/dwyx/CN/abstract/abstract5091.shtml |
| _version_ | 1797354097704173568 |
|---|---|
| author | WAN Yinghan GU Yexin YUAN Yunong TANG Min LU Li |
| author_facet | WAN Yinghan GU Yexin YUAN Yunong TANG Min LU Li |
| author_sort | WAN Yinghan |
| collection | DOAJ |
| description | Laboratory animals are the foundational conditions and indispensable technical support in life science research and biomedical industry development. The scientific development of animal models of diseases is of great significance to biomedical research and industrial development. In light of the booming development of multiple emerging in vitro modelling technologies over the past decade, in 2022, the U.S. Senate unanimously passed the bill FDA Modernization Act 2.0. This bill rescinded the requirement for animal testing in investigating the safety and effectiveness of a drug—a federal mandate since 1938, and highlighted the potential of various in vitro disease modeling approaches in future biomedical fields. This paper provides a comprehensive review of the latest advances and applications of in vitro disease modeling approaches in academia and industry followed by an interpretation of the FDA bill, namely cell culture, organoid, organ-on-a-chip, 3D bio-printing model and computer-based model. The paper next introduces the crossed applications of various disease models and discusses the advantages and disadvantages of each system, thereby providing insights into future trends in the use of animal disease models in China. |
| first_indexed | 2024-03-08T13:40:22Z |
| format | Article |
| id | doaj.art-8820817d43c14fc8b9ceb81bb4b04431 |
| institution | Directory Open Access Journal |
| issn | 1674-5817 |
| language | zho |
| last_indexed | 2024-03-08T13:40:22Z |
| publishDate | 2023-10-01 |
| publisher | Editorial Office of Laboratory Animal and Comparative Medicine |
| record_format | Article |
| series | Shiyan dongwu yu bijiao yixue |
| spelling | doaj.art-8820817d43c14fc8b9ceb81bb4b044312024-01-16T10:58:02ZzhoEditorial Office of Laboratory Animal and Comparative MedicineShiyan dongwu yu bijiao yixue1674-58172023-10-0143547248110.12300/j.issn.1674-5817.2023.0831674-5817（2023）05-0472-10Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0WAN Yinghan0GU Yexin1YUAN Yunong2TANG Min3LU Li4Shanghai Laboratory Animal Research Center, Shanghai 201203, ChinaCyberiad Biotechnology Ltd., Shanghai 201312, ChinaCyberiad Biotechnology Ltd., Shanghai 201312, ChinaCyberiad Biotechnology Ltd., Shanghai 201312, ChinaShanghai Laboratory Animal Research Center, Shanghai 201203, ChinaLaboratory animals are the foundational conditions and indispensable technical support in life science research and biomedical industry development. The scientific development of animal models of diseases is of great significance to biomedical research and industrial development. In light of the booming development of multiple emerging in vitro modelling technologies over the past decade, in 2022, the U.S. Senate unanimously passed the bill FDA Modernization Act 2.0. This bill rescinded the requirement for animal testing in investigating the safety and effectiveness of a drug—a federal mandate since 1938, and highlighted the potential of various in vitro disease modeling approaches in future biomedical fields. This paper provides a comprehensive review of the latest advances and applications of in vitro disease modeling approaches in academia and industry followed by an interpretation of the FDA bill, namely cell culture, organoid, organ-on-a-chip, 3D bio-printing model and computer-based model. The paper next introduces the crossed applications of various disease models and discusses the advantages and disadvantages of each system, thereby providing insights into future trends in the use of animal disease models in China.https://www.slarc.org.cn/dwyx/CN/abstract/abstract5091.shtmlanimal disease modelsin vitro disease modelsorganoidorgan-on-a-chip3d bio-printingfda modernization act 2.0 |
| spellingShingle | WAN Yinghan GU Yexin YUAN Yunong TANG Min LU Li Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 Shiyan dongwu yu bijiao yixue animal disease models in vitro disease models organoid organ-on-a-chip 3d bio-printing fda modernization act 2.0 |
| title | Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 |
| title_full | Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 |
| title_fullStr | Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 |
| title_full_unstemmed | Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 |
| title_short | Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 |
| title_sort | implications on the development of animal disease models from fda modernization act 2 0 |
| topic | animal disease models in vitro disease models organoid organ-on-a-chip 3d bio-printing fda modernization act 2.0 |
| url | https://www.slarc.org.cn/dwyx/CN/abstract/abstract5091.shtml |
| work_keys_str_mv | AT wanyinghan implicationsonthedevelopmentofanimaldiseasemodelsfromfdamodernizationact20 AT guyexin implicationsonthedevelopmentofanimaldiseasemodelsfromfdamodernizationact20 AT yuanyunong implicationsonthedevelopmentofanimaldiseasemodelsfromfdamodernizationact20 AT tangmin implicationsonthedevelopmentofanimaldiseasemodelsfromfdamodernizationact20 AT luli implicationsonthedevelopmentofanimaldiseasemodelsfromfdamodernizationact20 |